

510(k) Summary

APR 29 2009

PAS-Port™ Proximal Anastomosis System

510(k) Number	
Date Prepared	April 7, 2009
Applicant Information	900 Saginaw Redwood City, California 94063 Main: 650-364-9975 Fax: 650-331-7195
Contact Person	Kimberlee Leon Office: 650-331-7119 Fax: 650-331-7195 e-mail: leon@cardica.com
Establishment Registration Number	3004114958
Device Information	Classification Name: Clip, Implantable Regulation Number: 21 CFR §878.4300 Trade Name: Cardica® PAS-Port® Proximal Anastomosis System Common Name: Cardiovascular Surgical Instruments
Legally Marketed Predicate Device(s)	PAS-Port® Proximal Anastomosis System (K081225)
Device Description	The Cardica® PAS-Port® Proximal Anastomosis System is a mechanical device used to facilitate an aortic vein graft anastomosis. The connector replaces sutures to create a secure, patent and reproducible anastomosis. The PAS-Port® Proximal Anastomosis System consists of a connector and a delivery system.

Indications for Use	The PAS-Port® System is intended to create the aortic anastomosis of aortic autologous vein grafts.
Comparison to Predicate Device	The PAS-Port® Proximal Anastomosis System is substantially equivalent to the PAS-Port® Proximal Anastomosis System (K081225, 21 CFR §878.4300).
Device Testing Results and Conclusion	All necessary <i>in vitro</i> and <i>in vivo</i> testing has been performed on the PAS-Port® Proximal Anastomosis System and its packaging to ensure substantial equivalence to the predicate device, and to ensure the safety and effectiveness of the device.
Technological Characteristics	See Device Description above.
Substantial Equivalence Summary	Both, the Cardica® PAS-Port® Proximal Anastomosis System have the same indications for use and the same technological characteristics as the predicate device (K081225). This premarket notification has described the characteristics of the modified device in sufficient detail to assure substantial equivalence.
Conclusions	This Special 510(k) for Device Modification submission has demonstrated Substantial Equivalence as defined and understood in the Federal Food Drug and Cosmetic Act and various guidance documents issued by the Center for Devices and Radiological Health.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

APR 29 2009

Cardica, Inc.
c/o Ms. Kimberlee Leon
Manager, Quality Systems
900 Saginaw Drive
Redwood City, CA 94063

Re: K091017
Cardica® PAS-Port® Proximal Anastomosis System
Regulation Number: 21 CFR 870.4300
Regulation Name: Cardiovascular Surgical Instruments
Regulatory Class: Class II
Product Code: FZP
Dated: April 7, 2009
Received: April 9, 2009

Dear Ms. Leon:


We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometrics' (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



 Bram D. Zuckerman, M.D.
Division Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use Statement

510(k) Number:
(if known)

K091017

Device Name:

Cardica® PAS-Port® Proximal Anastomosis System

Indications for Use:

The Cardica® PAS-Port® Proximal Anastomosis System is intended to create the aortic anastomosis of aortic autologous vein grafts.

Prescription Use X
(Part 21 CFR§801.109)

OR Over-The-Counter Use _____
(Optional Format 1-2-96)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Thomas P. K. [Signature]
(Division Sign-Off)
Division of Cardiovascular Devices